- Home
- XPON vs GLMD Comparison
XPON vs GLMD Comparison
Compare XPON & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XPON | GLMD |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 6.6M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | XPON | GLMD |
|---|---|---|
| Price | $0.67 | $0.77 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 235.3K | 146.8K |
| Earning Date | 11-13-2025 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,417,947.00 | N/A |
| Revenue This Year | $61.26 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 109.37 | N/A |
| 52 Week Low | $0.60 | $0.73 |
| 52 Week High | $5.50 | $3.61 |
Technical Indicators
Market Signals| Indicator | XPON | GLMD |
|---|---|---|
| Relative Strength Index (RSI) | 24.14 | 32.44 |
| Support Level | $0.83 | $0.75 |
| Resistance Level | $1.26 | $1.00 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 2.06 | 9.86 |
Price Performance
Historical ComparisonAbout XPON Expion360 Inc.
Expion360 Inc is focused on the design, assembly, manufacturing, and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles (RV's) and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.